SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 713.61 thousand shares for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2016-02-25
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2014-12-31 was 60.83K shares, a 54.18% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2014-09-30 was 331.46K shares, a 470.35% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2014-06-30 was 136.71K shares, a 21.96% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2014-03-31 was 53.72K shares, a 830.29% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2015 was 713.61K shares, a 22.46% increase from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2014 was 582.72K shares, a 56.72% increase from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2013 was 371.82K shares, a 53.13% decline from fiscal 2012.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2012 was 793.25K shares, a 39.80% increase from fiscal 2011.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2015-12-31 | 713.61K shares 10-K · filed 2016-02-25 | ||||
| 2014-12-31 | 60.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | 392.29K shares derived: sum of 2 quarters · filed 2016-02-25 | 529.00K shares derived: sum of 3 quarters · filed 2016-02-25 | 582.72K shares 10-K · filed 2016-02-25 | |
| 2014-09-30 | 331.46K shares 10-Q · filed 2014-11-06 | 468.17K shares derived: sum of 2 quarters · filed 2014-11-06 | 521.89K shares 10-Q · filed 2014-11-06 | 654.63K shares derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | 136.71K shares 10-Q · filed 2014-08-07 | 190.43K shares 10-Q · filed 2014-08-07 | 323.17K shares derived: sum of 3 quarters · filed 2016-02-25 | 381.29K shares derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | 53.72K shares 10-Q · filed 2014-05-08 | 186.46K shares derived: sum of 2 quarters · filed 2016-02-25 | 244.58K shares derived: sum of 3 quarters · filed 2016-02-25 | 419.76K shares derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-31 | 132.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | 190.86K shares derived: sum of 2 quarters · filed 2016-02-25 | 366.04K shares derived: sum of 3 quarters · filed 2016-02-25 | 371.82K shares 10-K · filed 2016-02-25 | 374.82K shares 10-K · filed 2014-03-03 |
| 2013-09-30 | 58.12K shares 10-Q · filed 2014-11-06 | 233.30K shares derived: sum of 2 quarters · filed 2014-11-06 | 239.07K shares 10-Q · filed 2014-11-06 | 300.69K shares derived: sum of 4 quarters · filed 2015-02-26 | |
| 2013-06-30 | 175.18K shares 10-Q · filed 2014-08-07 | 180.96K shares 10-Q · filed 2014-08-07 | 242.57K shares derived: sum of 3 quarters · filed 2015-02-26 | 475.09K shares derived: sum of 4 quarters · filed 2015-02-26 | |
| 2013-03-31 | 5.77K shares 10-Q · filed 2014-05-08 | 67.39K shares derived: sum of 2 quarters · filed 2015-02-26 | 299.91K shares derived: sum of 3 quarters · filed 2015-02-26 | ||
| 2012-12-31 | 61.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | 294.14K shares derived: sum of 2 quarters · filed 2015-02-26 | 793.25K shares 10-K · filed 2015-02-26 | ||
| 2012-09-30 | 232.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | 731.64K shares 10-Q · filed 2012-11-07 | |||
| 2012-06-30 | 499.12K shares 10-Q · filed 2012-08-07 | ||||
| 2011-12-31 | 567.43K shares 10-K · filed 2014-03-03 | ||||
| 2010-12-31 | 391.42K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |